$0.11
(1.83%)
Add to watchlist
Create an alert
Stocks and Shares ISAUnicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Company Information
About this company
Key people
Shalabh Gupta
Chairman of the Board, President, Chief Executive Officer, Founder
John Townsend
Chief Financial Officer
Pramod Gupta
Executive Vice President - Pharmaceutical and Business Operations
Doug Jermasek
Executive Vice President - Corporate Strategy
Gaurav Aggarwal
Independent Director
Saraswati Kenkare-Mitra
Independent Director
Sandeep Laumas
Independent Director
Click to see more
Key facts
- Shares in issue21.49m
- EPICUNCY
- ISINUS90466Y2028
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$121.43m
- Employees22
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.